MedTrace Logo

Varenicline In-Patient Study

NCT01413516 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-11-14

Study results available
· View outcomes & findings →

Summary

This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Smoking cessation counseling

Counseling sessions provided by a trained smoking counselor

DRUG

Placebo

Sugar pill without any active medication

DRUG

Varenicline

Varenicline (an approved medication for smoking cessation)

Sponsors & Collaborators

Principal Investigators

  • Judith J Prochaska, PhD, MPH · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413516 on ClinicalTrials.gov